Key Insights

Highlights

Treatment Research

7 treatments under study, led by Epcoritamab

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 2 (1)

Trial Status

Active Not Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07883135Phase 2RecruitingPrimary

Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas

NCT03625037Phase 1/2Active Not Recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Epcoritamab2
  • Gemcitabine Oxaliplatin1
  • Glofitamab1
  • Obinutuzumab1
  • Oxaliplatin1

Active Sponsors

  • Genmab1
  • Genmab A/S1
  • AbbVie1
  • National Research Center for Hematology, Russia1

Top Investigators

Related Conditions

  • Primary Mediastinal Large Bcell Lymphoma Pmbcl1
  • Marginal Zone Lymphoma Mzl1
  • Dlbcl1
  • Mcl1
  • Fl1

Activity Timeline